| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 06/28/2022 | 19.52% | JP Morgan | $39 → $36 | Maintains | Neutral |
| 05/05/2022 | 115.8% | HC Wainwright & Co. | $75 → $65 | Maintains | Buy |
| 02/28/2022 | 2.92% | Morgan Stanley | $28 → $31 | Maintains | Equal-Weight |
| 02/24/2022 | 185.52% | Oppenheimer | $92 → $86 | Maintains | Outperform |
| 12/21/2021 | 75.96% | SVB Leerink | $56 → $53 | Maintains | Outperform |
| 12/14/2021 | 85.92% | SVB Leerink | $54 → $56 | Maintains | Outperform |
| 12/07/2021 | — | William Blair | Upgrades | Market Perform → Outperform | |
| 11/05/2021 | 112.48% | RBC Capital | $66 → $64 | Maintains | Outperform |
| 10/07/2021 | 125.76% | Jefferies | → $68 | Initiates Coverage On | → Buy |
| 08/04/2021 | 66% | Truist Securities | $45 → $50 | Upgrades | Hold → Buy |
| 06/28/2021 | 19.52% | JP Morgan | → $36 | Downgrades | Overweight → Neutral |
| 05/06/2021 | 32.8% | Canaccord Genuity | $45 → $40 | Maintains | Hold |
| 05/06/2021 | 311.69% | Roth Capital | $128 → $124 | Maintains | Buy |
| 04/14/2021 | 79.28% | SVB Leerink | → $54 | Initiates Coverage On | → Outperform |
| 03/12/2021 | 122.44% | Wolfe Research | → $67 | Initiates Coverage On | → Outperform |
| 01/20/2021 | 66% | Piper Sandler | $75 → $50 | Downgrades | Overweight → Neutral |
| 12/16/2020 | 49.4% | Morgan Stanley | $67 → $45 | Maintains | Equal-Weight |
| 12/15/2020 | 149% | HC Wainwright & Co. | → $75 | Assumes | → Buy |
| 12/03/2020 | 149% | RBC Capital | → $75 | Initiates Coverage On | → Outperform |
| 11/06/2020 | 49.4% | Canaccord Genuity | $64 → $45 | Maintains | Hold |
| 11/06/2020 | 122.44% | Morgan Stanley | $68 → $67 | Maintains | Equal-Weight |
| 11/06/2020 | 324.97% | Roth Capital | $131 → $128 | Maintains | Buy |
| 11/06/2020 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 10/13/2020 | 125.76% | Morgan Stanley | $75 → $68 | Maintains | Equal-Weight |
| 10/06/2020 | 238.65% | Evercore ISI Group | → $102 | Initiates Coverage On | → Outperform |
| 08/25/2020 | 281.81% | Raymond James | → $115 | Initiates Coverage On | → Outperform |
| 08/06/2020 | 291.77% | Stifel | $113 → $118 | Maintains | Buy |
| 07/20/2020 | 328.29% | Roth Capital | → $129 | Initiates Coverage On | → Buy |
| 07/13/2020 | 205.44% | B of A Securities | → $92 | Initiates Coverage On | → Buy |
| 07/01/2020 | 241.97% | Goldman Sachs | $91 → $103 | Upgrades | Neutral → Buy |
| 05/07/2020 | 235.33% | Oppenheimer | $88 → $101 | Maintains | Outperform |
| 05/07/2020 | 341.57% | Wells Fargo | $122 → $133 | Maintains | Overweight |
| 05/07/2020 | 149% | Morgan Stanley | $70 → $75 | Maintains | Equal-Weight |
| 04/28/2020 | 271.85% | Stifel | → $112 | Initiates Coverage On | → Buy |
| 04/15/2020 | 132.4% | Morgan Stanley | $71 → $70 | Maintains | Equal-Weight |
| 03/03/2020 | 135.72% | Morgan Stanley | $80 → $71 | Maintains | Equal-Weight |
| 01/31/2020 | — | SunTrust Robinson Humphrey | Downgrades | Buy → Hold | |
| 01/17/2020 | 165.6% | Morgan Stanley | $79 → $80 | Maintains | Equal-Weight |
| 12/17/2019 | 162.28% | JP Morgan | $58 → $79 | Maintains | Equal-Weight |
| 11/26/2019 | 198.8% | Janney Montgomery Scott | $75 → $90 | Maintains | Buy |
| 11/26/2019 | 271.85% | Nomura | $109 → $112 | Maintains | Buy |
| 11/25/2019 | 225.37% | Cantor Fitzgerald | $110 → $98 | Maintains | Overweight |
| 11/06/2019 | 66% | Canaccord Genuity | → $50 | Initiates Coverage On | → Hold |
| 10/09/2019 | 245.29% | Wells Fargo | $96 → $104 | Maintains | Outperform |
| 05/29/2019 | 149% | Goldman Sachs | → $75 | Assumes | → Neutral |
| 04/01/2019 | 218.73% | Wells Fargo | $85 → $96 | Maintains | Outperform |
| 03/05/2019 | 215.41% | Wedbush | $91 → $95 | Maintains | Outperform |
| 03/04/2019 | 89.24% | Morgan Stanley | $55 → $57 | Maintains | Equal-Weight |
| 02/22/2019 | — | Guggenheim | Initiates Coverage On | → Buy | |
| 12/19/2018 | 82.6% | Morgan Stanley | $54 → $55 | Maintains | Equal-Weight |
| 08/06/2018 | 165.6% | Piper Sandler | → $80 | Initiates Coverage On | → Overweight |
| 08/06/2018 | 142.36% | Wedbush | $70 → $73 | Maintains | Outperform |
| 06/28/2018 | 218.73% | Cantor Fitzgerald | $69 → $96 | Maintains | Overweight |
| 06/28/2018 | 261.89% | Nomura | $91 → $109 | Maintains | Buy |
| 06/27/2018 | 315.01% | HC Wainwright & Co. | $73 → $125 | Maintains | Buy |
| 05/08/2018 | 145.68% | Oppenheimer | $79 → $74 | Maintains | Outperform |
| 03/21/2018 | — | Morgan Stanley | Downgrades | Overweight → Equal-Weight | |
| 03/06/2018 | 102.52% | Morgan Stanley | $58 → $61 | Maintains | Overweight |
| 02/28/2018 | 139.04% | Cantor Fitzgerald | $61 → $72 | Maintains | Overweight |
| 02/14/2018 | 149% | Janney Montgomery Scott | → $75 | Initiates Coverage On | → Buy |
| 01/23/2018 | 165.6% | William Blair | → $80 | Initiates Coverage On | → Outperform |
| 12/01/2017 | 142.36% | HC Wainwright & Co. | → $73 | Initiates Coverage On | → Buy |
| 10/06/2017 | 85.92% | Morgan Stanley | $51 → $56 | Maintains | Overweight |
| 09/21/2017 | 69.32% | Needham | → $51 | Initiates Coverage On | → Buy |
| 08/04/2017 | 75.96% | Oppenheimer | → $53 | Initiates Coverage On | → Outperform |
| 07/10/2017 | 69.32% | Morgan Stanley | $53 → $51 | Maintains | Overweight |
Global Blood Therapeutics Questions & Answers
The latest price target for Global Blood Therapeutics (NASDAQ: GBT) was reported by JP Morgan on June 28, 2022. The analyst firm set a price target for $36.00 expecting GBT to rise to within 12 months (a possible 19.52% upside). 10 analyst firms have reported ratings in the last year.
The latest analyst rating for Global Blood Therapeutics (NASDAQ: GBT) was provided by JP Morgan, and Global Blood Therapeutics maintained their neutral rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Global Blood Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Global Blood Therapeutics was filed on June 28, 2022 so you should expect the next rating to be made available sometime around June 28, 2023.
While ratings are subjective and will change, the latest Global Blood Therapeutics (GBT) rating was a maintained with a price target of $39.00 to $36.00. The current price Global Blood Therapeutics (GBT) is trading at is $30.12, which is out of the analyst's predicted range.